Business Context and Reporting Period
This Form 8-K Current Report was filed by Kura Oncology, Inc. on December 10, 2022. The filing details updated clinical data from the KOMET-001 Phase 1/2 trial of ziftomenib, a menin inhibitor for acute myeloid leukemia (AML), presented at the 2022 Annual Meeting of the American Society of Hematology.
Key Financial Metrics
The filing text does not provide specific financial values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory milestones.
Material Changes and Clinical Results
- Phase 1a Results: Ziftomenib showed a wide therapeutic window in 30 patients with relapsed/refractory AML. One patient with NPM1-mutant AML achieved complete remission (CR) with no minimal residual disease (MRD) after seven prior lines of therapy and remained on treatment for two years.
- Phase 1b Dose Selection: A total of 53 patients were treated in randomized expansion cohorts (17 at 200 mg, 36 at 600 mg). The 600 mg dose demonstrated optimal clinical benefit.
- Efficacy in NPM1-mutant AML: At 600 mg, the CR rate was 30% (6/20 patients) compared to 17% (1/6) at 200 mg. Four of the six CR patients had IDH and/or FLT3 co-mutations. Of five patients assessed for MRD at 600 mg, three were MRD negative.
- Efficacy in KMT2A-rearranged AML: Only one patient achieved CR/CRh. Differentiation syndrome (DS) symptoms prevented most patients from receiving sufficient therapy to meet response criteria.
- Safety Profile: Continuous daily dosing was well tolerated. No drug-induced QTc prolongation was observed. Differentiation syndrome was the most common adverse event, occurring in 20% of NPM1-mutant patients at 600 mg (mostly Grade 1-2) and approximately 38% of KMT2A-rearranged patients.
Guidance, Outlook, and Management Commentary
- Recommended Dose: Following a positive Type C meeting with the FDA, 600 mg is the recommended Phase 2 dose for ziftomenib in NPM1-mutant AML.
- Regulatory Alignment: Key elements of a registration-enabling study design were agreed upon with the FDA.
- Timeline: The Company expects to dose the first patient in the Phase 2 registration-directed trial in the first quarter of 2023.
- Future Strategy: Subsequent studies will prioritize combination therapies with venetoclax and FLT3 inhibitors in both frontline and relapsed/refractory settings. Management believes combining ziftomenib with standards of care can mitigate differentiation syndrome in KMT2A-rearranged patients.
- Risks: Forward-looking statements are subject to risks including clinical trial efficacy, regulatory approval uncertainties, reliance on third parties, and capital requirements.
Investor Verification Checklist
- Verify the initiation date of the Phase 2 registration-directed trial in Q1 2023.
- Monitor the management of differentiation syndrome in KMT2A-rearranged patients during upcoming combination studies.
- Review the specific design of the registration-enabling study agreed upon with the FDA.
- Track the company's cash runway and financing activities, as this filing does not disclose current liquidity levels.